The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-28 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
This reasoning was conditioned by Russia's historical experiences, given the frequency with which the country had been invaded over the preceding 150 years. The Second World War experience was particularly dramatic for the Russians: the Soviet Union suffered unprecedented devastation as a result of the Nazi onslaught, and over 20 million Soviet citizens died during the war; tens of thousands of Soviet cities, towns, and villages were leveled; and 30,100 Soviet factories were destroyed. In order to prevent a similar assault in the future, Stalin was determined to use the Red Army to gain control of Poland, to dominate the Balkans and to destroy utterly Germany's capacity to engage in another war. The problem was that Stalin's strategy risked confrontation with the equally powerful United States, who viewed Stalin's actions as a flagrant violation of the Yalta agreement. At the end of the war in Europe, in May 1945, the Soviets insisted on occupying the Danish island of Bornholm, due to its strategic position at the entrance to the Baltic. When the local German commander insisted on surrendering to the Western Allies, as did German forces in the rest of Denmark, the Soviets bombed the island, causing heavy casualties and damage among a civilian population which was only lightly touched throughout the war, and then invaded the island and occupied it until mid-1946—all of which can be considered as initial moves in the Cold War.
DBH-like monooxygenase protein 1, also known as monooxygenase X, is an enzyme that in humans is encoded by the MOXD1 gene. DBH-like 1 maintains many of the structural features of dopamine beta-monooxygenase DBH. Since Peptidylglycine alpha-hydroxylating monooxygenase (PHM; EC 1.14.17.3) is homologous to dopamine beta-monooxygenase (DBM; EC 1.14.17.1) this concerns a structural basis for a new family of copper type II, significantly specific for ascorbate-dependent monooxygenases based on the corresponding mouse homolog. The pathway of catecholamine synthesis is a possible catecholamine-binding metabolic copper enzyme domain, a neuron-like property encoding MOX without a signal sequence enzyme metabolism resolving the monooxygenase X chemical pathway of an unknown substrate, exogenous MOX is not secreted, and it localizes throughout the endoplasmic reticulum, in both endocrine or nonendocrine cells.
=== Trial === When the case reached the Old Bailey in September 1994, Mr Justice Ognall ruled that the police had shown "excessive zeal" and had tried to incriminate Stagg by "deceptive conduct of the grossest kind". He excluded all the entrapment evidence on the grounds that Stagg's descriptions of the murder were not nearly as close to the reality as the police had maintained. With no other evidence to present, the prosecution withdrew its case and Stagg was acquitted. Keith Pedder, the case's lead detective, received heavy public criticism. Even after Stagg was (rightfully as it later turned out) cleared of the murder of Nickell, Pedder continued over subsequent years to promote his theory that Stagg was guilty. He told an ITV Real Crime documentary in 2001:
=== Inorganic biochemistry === Sarkar organized and chaired the first international meeting of Inorganic Biochemistry in the boardroom of SickKids with 35 participants in 1972, which included, among others, R. J. P. Williams (Oxford), Gerhard Schrauzer (University of California, San Diego), David R. Williams (Saint Andrews University, UK), David A Brown (University College Dublin) and Barry Lever (York University). To acknowledge this new discipline the 56th Nobel Symposium introducing Inorganic Biochemistry was held in Sweden under the auspices of the Nobel Foundation in 1982 where Sarkar was an invited speaker. He organized various series of symposia on metals and genetics beginning in 1994 and edited several books on metals in biology, metal-related diseases, and metals in the environment. He was a member of the committee to establish terminology relating to -omics and metals under the auspices of the International Union of Pure and Applied Chemistry (IUPAC).
=== Primary cold agglutinin disease === In single-center series, primary CAD has been found to account for 13–15% of the cases of AIHA. In a population-based clinical study of primary CAD in Norway, the prevalence was found to be 16 per million in habitants and the incidence rate 1 per million inhabitants per year. Little is known about possible geographic variations. Median age of CAD patients was 76 years and median age at onset of symptoms was approximately 67 years. The male/female ratio has been reported to be 0.5–0.6 which is not very different from a male/female ratio of 0.72 in an age-matched general population. The frequency of auto-immune disorders other than CAD does probably not differ from what is to be expected in an elderly population with some female predominance. as about 12.5 years from diagnosis and median age at death was 82 years, which implies a life expectancy in these patients similar to that of an age-matched general population. More than 90% of patients with primary CAD have Cold-induced circulatory symptoms ranging from moderate acrocyanosis to severe Raynaud phenomena precipitated even by very slight cold exposure.
Sources: en.wikipedia.org
Kyle Hardingham (born 1 September 1988) is a former professional Australian rules footballer who played for the Essendon Football Club in the Australian Football League (AFL). Hardingham was selected by Essendon with the seventh pick in the 2010 AFL Pre-Season Draft. Originally from East Fremantle in the WAFL, he represented Western Australia in the state game against South Australia in 2009. He made his AFL debut against North Melbourne in round 17 of the 2010 AFL season, kicking four goals, helping Essendon achieve an upset victory by 3 points. The following Friday night, he kicked two goals in a win against St Kilda. He managed to kick two goals once again in the next game, a 76-point loss to Carlton, although he also kicked two behinds as part of the wayward kicking by the entire Essendon team, which managed 9.19 for the night. Hardingham was delisted at the conclusion of the 2014 AFL season. He remained with Essendon as a VFL-listed player in its reserves team in 2016. Hardingham, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 season.
== Safety considerations == PABA is largely nontoxic; the median lethal dose of PABA in dogs (oral) is 2 g/kg. Allergic reactions, specifically allergic contact dermatitis and photocontact dermatitis, to PABA can occur. It is formed in the metabolism of certain ester-type local anesthetics, and many allergic reactions to local anesthetics are the result of reactions to PABA.
=== Welsh === Llanfairpwllgwyngyllgogerychwyrndrobwllllantysiliogogogoch, a railway station on the island of Anglesey in Wales, is the longest place name in the Welsh language. At 51 letters in the Welsh alphabet (the digraphs ll and ch are each collated as single letters) the name can be translated as "St Mary's church in the hollow of the white hazel near to the rapid whirlpool and the church of St Tysilio of the red cave". However, it was artificially contrived in the 1860s as a publicity stunt, to give the station the longest name of any railway station in the United Kingdom. Long words are comparatively rare in Welsh. Candidates for long words other than proper nouns include the following (the digraph dd is also treated as a single letter, as is ng in many instances including in the last word below):
Genetically modified crops are genetically modified plants that are used in agriculture. The first crops developed were used for animal or human food and provide resistance to certain pests, diseases, environmental conditions, spoilage or chemical treatments (e.g. resistance to a herbicide). The second generation of crops aimed to improve the quality, often by altering the nutrient profile. Third generation genetically modified crops could be used for non-food purposes, including the production of pharmaceutical agents, biofuels, and other industrially useful goods, as well as for bioremediation.
Sources: en.wikipedia.org
=== Gradual dissolution === In March 2002, the governments of Montenegro and Serbia, along with the Federal Republic of Yugoslavia (FRY), signed the Accord on Principles in Relations between Serbia and Montenegro (commonly known as the Belgrade Agreement), which outlined the restructuring of their mutual relations. This agreement led to the adoption of the Constitutional Charter of Serbia and Montenegro on 4 February 2003, officially transforming the FRY into the State Union of Serbia and Montenegro and formally retiring the name "Yugoslavia" after 74 years. The Constitutional Charter included a provision allowing either republic to hold a referendum on independence after a three-year transition period. On 21 May 2006, Montenegro held such a referendum. The final results showed that 55.5% of voters supported independence, narrowly surpassing the 55% threshold set by the European Union for the referendum's validity. Voter turnout was 86.5%. Following the referendum, Montenegro's parliament formally declared independence on 3 June 2006. Subsequently, on 5 June 2006, Serbia's parliament did the same, effectively dissolving the union and marking the final chapter in the disintegration of the former Yugoslavia.
==== Labeling ==== For US food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For selenium labeling purposes, 100% of the Daily Value was 70 μg, but as of 27 May 2016 it was revised to 55 μg. A table of the old and new adult daily values is provided at Reference Daily Intake.
Ablukast (INN) is an experimental drug that is a leukotriene antagonist. It was investigated for potential applications in the treatment of inflammatory conditions, including asthma, skin disorders, and inflammatory bowel disease. It reached Phase III clinical trials, but development was discontinued in 1996.
Uterine prolapse is a form of pelvic organ prolapse in which the uterus and a portion of the upper vagina protrude into the vaginal canal and, in severe cases, through the opening of the vagina. It is most often caused by injury or damage to structures that hold the uterus in place within the pelvic cavity. Symptoms may include vaginal fullness, pain with sexual intercourse, difficulty urinating, and urinary incontinence. Risk factors include older age, pregnancy, vaginal childbirth, obesity, chronic constipation, and chronic cough. Prevalence, based on physical exam alone, is estimated to be approximately 14%. Diagnosis is based on a symptom history and physical examination, including pelvic examination. Preventive efforts include managing medical risk factors, such as chronic lung conditions, smoking cessation, and maintaining a healthy weight. Management of mild cases of uterine prolapse include pelvic floor therapy and pessaries. More severe cases may require surgical intervention - options include uterine suspension (hysteropexy); removal of the uterus (partial or supra-cervical hysterectomy) with surgical fixation of the vaginal vault to a nearby pelvic structure; or permanent surgical closure of the vagina (colpocleisis). Outcomes following management are generally positive with reported improvement in quality of life.
Imidazole can also be formed in a vapor-phase reaction. The reaction occurs with formamide, ethylenediamine, and hydrogen over platinum on alumina, and it must take place between 340 and 480 °C. This forms a very pure imidazole product. The Van Leusen reaction can also be employed to form imidazoles starting from TosMIC and an aldimine. The Van Leusen Imidazole Synthesis allows the preparation of imidazoles from aldimines by reaction with tosylmethyl isocyanide (TosMIC). The reaction has later been expanded to a two-step synthesis in which the aldimine is generated in situ: the Van Leusen Three-Component Reaction (vL-3CR). Imidazolin-5-one derivatives can be synthesized from Oxazolidin-5-ones via amidification followed by dehydration. in this reaction, the Oxazolidin-5-ones were condensed with primary amines like aniline, sulfonamides etc. in the presence of various of catalysts like dry pyridine or glacial acetic acid + sodium acetate or glacial acetic acid + red brick powder to yield Imidazolin-5-one derivatives.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.